Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patient-guided TKI dose reduction in chronic myeloid leukemia
2021-006581-20Phase 4Active
- Sponsor
- Radboud University Medical Center
- Start
- Feb 2022
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of imatinib, dasatinib, bosutinib, nilotinib and ponatinib in chronic myelogenous leukemia (CML), sponsored by Radboud University Medical Center. Primary endpoint: Proportion of patients with loss of major molecular response at 12 months after dose reduction. Started Feb 2022; status: active.
02
Drugs
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2021-006581-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006581-20.